222 related articles for article (PubMed ID: 34034619)
21. Mutant LKB1 Confers Enhanced Radiosensitization in Combination with Trametinib in KRAS-Mutant Non-Small Cell Lung Cancer.
Wang Y; Li N; Jiang W; Deng W; Ye R; Xu C; Qiao Y; Sharma A; Zhang M; Hung MC; Lin SH
Clin Cancer Res; 2018 Nov; 24(22):5744-5756. PubMed ID: 30068711
[No Abstract] [Full Text] [Related]
22. ERRα suppression enhances the cytotoxicity of the MEK inhibitor trametinib against colon cancer cells.
Zhou S; Xia H; Xu H; Tang Q; Nie Y; Gong QY; Bi F
J Exp Clin Cancer Res; 2018 Sep; 37(1):218. PubMed ID: 30185207
[TBL] [Abstract][Full Text] [Related]
23. Dasatinib sensitises KRAS-mutant cancer cells to mitogen-activated protein kinase kinase inhibitor via inhibition of TAZ activity.
Rao G; Kim IK; Conforti F; Liu J; Zhang YW; Giaccone G
Eur J Cancer; 2018 Aug; 99():37-48. PubMed ID: 29902613
[TBL] [Abstract][Full Text] [Related]
24. Effect of Metformin in Combination With Trametinib and Paclitaxel on Cell Survival and Metastasis in Melanoma Cells.
Lee Y; Park D
Anticancer Res; 2021 Mar; 41(3):1387-1399. PubMed ID: 33788730
[TBL] [Abstract][Full Text] [Related]
25. EGFR and HER2 signals play a salvage role in MEK1-mutated gastric cancer after MEK inhibition.
Mizukami T; Togashi Y; Sogabe S; Banno E; Terashima M; De Velasco MA; Sakai K; Fujita Y; Tomida S; Nakajima TE; Boku N; Nishio K
Int J Oncol; 2015 Aug; 47(2):499-505. PubMed ID: 26081723
[TBL] [Abstract][Full Text] [Related]
26. MEK inhibition suppresses metastatic progression of KRAS-mutated gastric cancer.
Yamasaki J; Hirata Y; Otsuki Y; Suina K; Saito Y; Masuda K; Okazaki S; Ishimoto T; Saya H; Nagano O
Cancer Sci; 2022 Mar; 113(3):916-925. PubMed ID: 34931404
[TBL] [Abstract][Full Text] [Related]
27. Targeting MEK in a Translational Model of Histiocytic Sarcoma.
Takada M; Hix JML; Corner S; Schall PZ; Kiupel M; Yuzbasiyan-Gurkan V
Mol Cancer Ther; 2018 Nov; 17(11):2439-2450. PubMed ID: 30135215
[TBL] [Abstract][Full Text] [Related]
28. The Combination of Trametinib, a MEK Inhibitor, and Temsirolimus, an mTOR Inhibitor, Radiosensitizes Lung Cancer Cells.
Kim SY; Jeong EH; Lee TG; Kim HR; Kim CH
Anticancer Res; 2021 Jun; 41(6):2885-2894. PubMed ID: 34083279
[TBL] [Abstract][Full Text] [Related]
29. Combined inhibition of MEK and PI3K pathways overcomes acquired resistance to EGFR-TKIs in non-small cell lung cancer.
Sato H; Yamamoto H; Sakaguchi M; Shien K; Tomida S; Shien T; Ikeda H; Hatono M; Torigoe H; Namba K; Yoshioka T; Kurihara E; Ogoshi Y; Takahashi Y; Soh J; Toyooka S
Cancer Sci; 2018 Oct; 109(10):3183-3196. PubMed ID: 30098066
[TBL] [Abstract][Full Text] [Related]
30. The mTORC1/2 Inhibitor AZD8055 Strengthens the Efficiency of the MEK Inhibitor Trametinib to Reduce the Mcl-1/[Bim and Puma] ratio and to Sensitize Ovarian Carcinoma Cells to ABT-737.
Pétigny-Lechartier C; Duboc C; Jebahi A; Louis MH; Abeilard E; Denoyelle C; Gauduchon P; Poulain L; Villedieu M
Mol Cancer Ther; 2017 Jan; 16(1):102-115. PubMed ID: 27980105
[TBL] [Abstract][Full Text] [Related]
31. Trametinib overcomes KRAS-G12V-induced osimertinib resistance in a leptomeningeal carcinomatosis model of EGFR-mutant lung cancer.
Fukuda K; Otani S; Takeuchi S; Arai S; Nanjo S; Tanimoto A; Nishiyama A; Naoki K; Yano S
Cancer Sci; 2021 Sep; 112(9):3784-3795. PubMed ID: 34145930
[TBL] [Abstract][Full Text] [Related]
32. Organoids of patient-derived medullary thyroid carcinoma: The first milestone towards a new in vitro model in dogs.
Scheemaeker S; Inglebert M; Daminet S; Dettwiler M; Letko A; Drögemüller C; Kessler M; Ducatelle R; Rottenberg S; Campos M
Vet Comp Oncol; 2023 Mar; 21(1):111-122. PubMed ID: 36583463
[TBL] [Abstract][Full Text] [Related]
33. The MEK inhibitor trametinib separates murine graft-versus-host disease from graft-versus-tumor effects.
Itamura H; Shindo T; Tawara I; Kubota Y; Kariya R; Okada S; Komanduri KV; Kimura S
JCI Insight; 2016 Jul; 1(10):e86331. PubMed ID: 27699218
[TBL] [Abstract][Full Text] [Related]
34. Trametinib alleviates lipopolysaccharide-induced acute lung injury by inhibiting the MEK-ERK-Egr-1 pathway.
Chen S; Xu H; Ye P; Wu C; Ding X; Chen S; Zhang H; Zou Y; Zhao J; Le S; Wu J; Chen S; Xia J
Int Immunopharmacol; 2020 Mar; 80():106152. PubMed ID: 31926447
[TBL] [Abstract][Full Text] [Related]
35. Enhancing Therapeutic Efficacy of Oncolytic Herpes Simplex Virus with MEK Inhibitor Trametinib in Some BRAF or KRAS-Mutated Colorectal or Lung Carcinoma Models.
Zhou X; Zhao J; Zhang JV; Wu Y; Wang L; Chen X; Ji D; Zhou GG
Viruses; 2021 Sep; 13(9):. PubMed ID: 34578339
[TBL] [Abstract][Full Text] [Related]
36. Trametinib and dactolisib but not regorafenib exert antiproliferative effects on rat pancreatic stellate cells.
Witteck L; Jaster R
Hepatobiliary Pancreat Dis Int; 2015 Dec; 14(6):642-50. PubMed ID: 26663013
[TBL] [Abstract][Full Text] [Related]
37. MEK inhibitor trametinib does not prevent the growth of anaplastic lymphoma kinase (ALK)-addicted neuroblastomas.
Umapathy G; Guan J; Gustafsson DE; Javanmardi N; Cervantes-Madrid D; Djos A; Martinsson T; Palmer RH; Hallberg B
Sci Signal; 2017 Nov; 10(507):. PubMed ID: 29184034
[TBL] [Abstract][Full Text] [Related]
38. Trametinib radiosensitises RAS- and BRAF-mutated melanoma by perturbing cell cycle and inducing senescence.
Schick U; Kyula J; Barker H; Patel R; Zaidi S; Gregory C; Hafsi H; Roulstone V; Deutsch E; McLaughlin M; Harrington K
Radiother Oncol; 2015 Nov; 117(2):364-75. PubMed ID: 26163092
[TBL] [Abstract][Full Text] [Related]
39. The MEK Inhibitor Trametinib Ameliorates Kidney Fibrosis by Suppressing ERK1/2 and mTORC1 Signaling.
Andrikopoulos P; Kieswich J; Pacheco S; Nadarajah L; Harwood SM; O'Riordan CE; Thiemermann C; Yaqoob MM
J Am Soc Nephrol; 2019 Jan; 30(1):33-49. PubMed ID: 30530834
[TBL] [Abstract][Full Text] [Related]
40. Growth arrest by activated BRAF and MEK inhibition in human anaplastic thyroid cancer cells.
Kurata K; Onoda N; Noda S; Kashiwagi S; Asano Y; Hirakawa K; Ohira M
Int J Oncol; 2016 Dec; 49(6):2303-2308. PubMed ID: 27748799
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]